Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset——Joint poster presentation with Bachem to ...
Presentation Date/Time: Saturday, December 7, 2024, 5:30 p.m. PT Presenting Speaker: Alissa Brandes, Ph.D.
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Initial data from the dose escalation phase using a July 15, 2024 data cutoff date indicate that ...
Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease ...
AstraZeneca and TotalEnergies are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting ...
The poster to be presented at ASH 2024 will provide a clinical update of the ongoing first-in-human dose-escalation phase 1/2a study of MP0533 in patients with relapsed/refractory acute myeloid ...
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...
allowing for control of tumors in vivo without the need for exogenous or engineered cytokines- - Posters include demonstration of advances in gene editing and transgene design that enable greater ...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMTâ„¢ plus immune check point inhibitor in metastatic breast cancer Presentations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback